US Patent 9,763,883: Claim Scope, Xtampza ER Relevance, and Abuse-Deterrent Oxycodone Patent Landscape
US Patent No. 9,763,883 protects abuse-deterrent microparticles made by converting a basic drug into a fatty-acid salt within a wax or wax-like carrier. The broadest claim requires both a specific composition and a specific manufacturing process: dissolving the free-base active agent in a fatty-acid melt containing fatty acid in molar excess. The commercial center of gravity is the oxycodone/myristic-acid/beeswax/carnauba-wax embodiment associated with Collegium Pharmaceutical's DETERx technology and Xtampza ER.
The patent is materially narrower than a general claim to abuse-deterrent oxycodone. A competing product that lacks the claimed fatty-acid salt, wax microparticle structure, or process limitation should have a substantial noninfringement position, although other patents may apply.
What does US Patent 9,763,883 protect?
The patent protects solid microparticles containing:
- A fatty-acid salt of a basic, abuse-prone active agent; and
- One or more waxes or wax-like carrier materials.
The microparticles must be made by dissolving the active agent in free-base form in a melt containing one or more fatty acids. The fatty acids must be present in molar excess relative to the active agent.
The claim architecture is cumulative. A product generally must satisfy all of the following elements to fall within claim 1:
| Required element |
Claim requirement |
| Dosage material |
Solid microparticles |
| Drug |
Basic active agent prone to abuse |
| Drug form |
Fatty-acid salt |
| Carrier |
Wax, wax-like substance, or mixture |
| Manufacturing step |
Free-base drug dissolved in fatty-acid melt |
| Stoichiometry |
Fatty acid in molar excess |
| Product use |
Abuse-deterrent, therapeutically effective composition |
The phrase "abuse-deterrent" is tied to the claimed composition, but it does not automatically cover every formulation that receives an FDA abuse-deterrent labeling designation. FDA labeling and patent infringement are separate analyses.
How broad is independent claim 1?
Claim 1 is broad across drug identity and excipient identity but narrow across formulation architecture and manufacturing method.
It does not limit the active agent to oxycodone. The claim can cover any basic active agent prone to abuse that forms the required fatty-acid salt and is incorporated into the claimed wax-based microparticles. Claim 18 expressly identifies oxycodone, hydrocodone, morphine, oxymorphone, amphetamine, and methylphenidate, but the open-ended language of claim 1 is potentially broader.
The claim does not require:
- A particular release profile;
- A particular capsule size;
- A specified drug loading;
- A particular dissolution-test result;
- A specific route of administration;
- A particular abuse-deterrence mechanism such as resistance to crushing, extraction, or injection;
- A particular commercial product.
The manufacturing limitation is important. Claim 1 is written as a composition claim that incorporates a process limitation. In U.S. patent law, a product-by-process limitation generally must be considered in infringement analysis. The relevant question is not only whether the accused product has similar ingredients, but also whether it has the claimed product characteristics and was made through the recited process, depending on the governing interpretation and evidence. Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009).
What do claims 2 through 12 add?
Claims 2 through 12 narrow the fatty-acid stoichiometry, fatty-acid identity, carrier ratio, and wax selection.
| Claims |
Limitation |
Commercial significance |
| 2 |
Fatty acid at 2 to 15 times the molar amount of drug |
Broad excess range |
| 3 |
2 to 10 molar equivalents |
Narrower overlapping range |
| 4 |
6.9 to 15 equivalents |
High-excess range |
| 5 |
6.9 to 10 equivalents |
Narrow high-excess range |
| 6 |
C5-C30 monovalent or C8-C40 divalent fatty acids |
Defines acid classes |
| 7 |
Enumerated saturated and unsaturated fatty acids |
Detailed species list |
| 8 |
Myristic acid |
Key oxycodone embodiment |
| 9 |
Carrier at 0.25 to 8 times drug weight |
Broad carrier loading |
| 10 |
Carrier at 2 to 6 times drug weight |
Narrower carrier range |
| 11 |
Carnauba wax, beeswax, microcrystalline wax, or mixtures |
Limits carrier identity |
| 12 |
Beeswax and carnauba wax mixture |
Commercially important wax combination |
The overlapping molar ranges in claims 2 through 5 create fallback positions. A formulation outside the 6.9-to-10 range could still fall within claim 2 or claim 3 if it uses between 2 and 10 or 2 and 15 equivalents. A formulation using fewer than two equivalents, however, would not meet those dependent claims, although claim 1 would still require only a molar excess.
What is the narrow oxycodone embodiment?
Claims 13 and 15 are the most commercially focused claims. They require:
- Oxycodone;
- Myristic acid;
- Beeswax and carnauba wax; and
- The claimed microparticle composition or a dosage form containing it.
Claim 13 is a composition claim. Claim 15 covers a pharmaceutical dosage form containing that composition. Claims 16 and 17 further limit the dosage form to a capsule.
This creates a layered infringement position:
- Claim 1 reaches the general fatty-acid-salt microparticle platform.
- Claims 8, 11, and 12 narrow the chemistry and wax carrier.
- Claim 13 reaches the specific oxycodone/myristic-acid/wax composition.
- Claims 15 and 17 extend the species coverage into dosage forms and capsules.
A generic or competing oxycodone product would face the highest literal-infringement risk if it uses oxycodone free base converted in situ with myristic acid and embeds the resulting material in beeswax/carnauba-wax microparticles.
Which active agents are expressly covered?
Claim 18 identifies six active-agent classes or species:
| Active agent |
Claim coverage |
| Oxycodone |
Claims 13, 15, 19 and broader claims |
| Hydrocodone |
Claim 20 and broader claims |
| Morphine |
Claim 18 |
| Oxymorphone |
Claim 18 |
| Amphetamine |
Claim 18 |
| Methylphenidate |
Claim 18 |
Claim 19 narrows claim 18 to oxycodone. Claim 20 narrows it to hydrocodone.
The dependent claims do not necessarily define the full universe of covered drugs. Claim 1 is not expressly limited to the six compounds in claim 18. Other basic controlled substances could be implicated if they satisfy the structural, formulation, and manufacturing requirements.
What patent protects Xtampza ER?
Xtampza ER is an extended-release oxycodone product marketed by Collegium Pharmaceutical using the DETERx abuse-deterrent platform. FDA approved Xtampza ER in 2016 as an extended-release oxycodone product.[2]
US Patent 9,763,883 is directed to the same type of technical architecture reflected in the Xtampza ER formulation: oxycodone incorporated into abuse-deterrent, wax-based microparticles. The patent is therefore commercially relevant to Xtampza ER and to abbreviated new drug applications that reference the product.
The patent does not, by itself, establish that every Xtampza ER manufacturing step or every commercial formulation is covered by every claim. Commercial products may be protected by multiple continuation, divisional, or later-issued patents. FDA Orange Book listings must be reviewed patent by patent and claim by claim.[3]
What is the Orange Book status of US 9,763,883?
US 9,763,883 has been associated with the Xtampza ER patent estate and is relevant to Orange Book-based generic entry analysis. Orange Book listing is significant because it can support a statutory patent certification process and, for a timely Paragraph IV notice, may trigger the Hatch-Waxman 30-month litigation stay if the NDA holder or patent owner brings suit within the statutory period.[4]
An Orange Book listing does not mean that all claims are necessarily valid or infringed. It also does not prevent a generic applicant from filing a Paragraph IV certification. The listing identifies the patent as one asserted to cover the drug, formulation, or approved method of use.
When does US Patent 9,763,883 lose exclusivity?
The patent issued on September 19, 2017. Its ordinary U.S. patent term is expected to extend into 2033, subject to the patent's actual priority chain, patent-term adjustment, terminal disclaimers, and any applicable regulatory extension.[1]
The practical generic-entry date depends on more than the nominal patent expiration date. Relevant factors include:
- The filing date of an ANDA;
- The certification selected by the applicant;
- The date of Paragraph IV notice;
- Whether the patent owner files suit;
- The duration of the 30-month stay;
- Any court-ordered injunction;
- Other Orange Book-listed patents;
- FDA exclusivity separate from patent rights; and
- Any settlement agreement.
FDA approval of a generic after expiration of one listed patent may still be blocked by other unexpired patents covering the same product.
What Paragraph IV risks apply?
A Paragraph IV challenge to claim 1 could attack several elements:
Lack of novelty
A challenger could identify prior art disclosing wax microparticles containing a basic drug, fatty-acid salts of the drug, or in situ salt formation in a fatty-acid melt. The strongest novelty reference would need to disclose the full combination, including the molar-excess requirement and process sequence.
Obviousness
Obviousness is the more substantial technical challenge. A challenger could combine references describing:
- Fatty-acid salts of basic drugs;
- Melt granulation;
- Wax-based controlled-release particles;
- Abuse-deterrent opioid formulations; and
- Excess fatty acid to improve salt formation or drug distribution.
The patent's defensible distinction is the particular integration of salt formation and wax microparticle production, especially the high molar-excess ranges and the oxycodone/myristic-acid embodiment.
Written description and enablement
The Markush scope of claim 1 extends beyond oxycodone. A challenger could argue that the specification does not adequately support the full universe of basic abuse-prone agents, fatty acids, waxes, and processing conditions. Claims 13 through 17 are less exposed to this argument because they are directed to a defined oxycodone formulation.
Infringement avoidance
An ANDA applicant could design around the claims by using:
- A preformed oxycodone salt rather than converting free-base oxycodone in a fatty-acid melt;
- A non-wax polymeric carrier;
- A fatty-acid amount that is not in molar excess;
- A non-microparticle dosage structure;
- A different fatty acid and carrier combination;
- A manufacturing route that avoids the claimed process limitation.
A design-around may still implicate other patents in the broader DETERx or abuse-deterrent oxycodone estate.
How does this patent compare with conventional oxycodone patents?
| Issue |
US 9,763,883 |
Conventional oxycodone patent |
| Primary subject |
Abuse-deterrent microparticles |
Drug substance, dosage form, or method |
| Core technology |
Fatty-acid salt plus wax carrier |
May use HCl salt, polymer matrix, coating, or tablet |
| Process limitation |
Yes |
May be absent |
| Drug specificity |
Broad in claim 1; oxycodone claims 13, 15, 19 |
Often oxycodone-specific |
| Dosage form |
Capsule claims included |
Tablet or capsule depending patent |
| Relevance to ordinary oxycodone IR |
Limited |
Potentially direct |
| Relevance to Xtampza ER |
High |
High only if product-specific |
| Relevance to biologics |
None |
None |
This patent is a small-molecule formulation patent, not a biologic patent. Biosimilar risk is therefore not applicable. The competitive threat comes from ANDA applicants and branded abuse-deterrent opioid products, not from a 351(k) biosimilar pathway.
Which companies are potential competitors?
The principal commercial comparison is with companies developing extended-release or abuse-deterrent opioid products, including:
- Collegium Pharmaceutical, associated with Xtampza ER;
- Purdue Pharma, associated with OxyContin and related abuse-deterrent technology;
- Endo, associated with Opana ER before its market withdrawal;
- Alkermes, associated with proprietary abuse-deterrent and long-acting drug-delivery technologies; and
- Generic manufacturers seeking approval for oxycodone or hydrocodone products.
The relevant competitive question is not whether a company markets oxycodone. It is whether its product uses the claimed fatty-acid-salt and wax-microparticle architecture.
How strong is the patent estate?
US 9,763,883 has meaningful commercial value because it targets a product-defining formulation rather than only a broad therapeutic use. Its strongest features are:
- The specific oxycodone embodiment;
- Myristic acid as a defined fatty acid;
- Beeswax and carnauba wax as defined carriers;
- Nested fallback concentration ranges;
- Coverage of both compositions and capsules;
- Relevance to an FDA-approved abuse-deterrent product.
Its principal vulnerabilities are:
- The process limitation embedded in claim 1;
- Potential prior art combining fatty-acid salts with wax matrices;
- The breadth of the basic-active-agent genus;
- Potential design-around using a different salt-formation process;
- Dependence on other patents for complete commercial exclusivity.
Key Takeaways
- US 9,763,883 protects wax-based microparticles containing fatty-acid salts of abuse-prone basic drugs.
- Claim 1 requires a free-base drug to be dissolved in a fatty-acid melt with fatty acid in molar excess.
- Claims 13 and 15 are directed to the commercially important oxycodone, myristic acid, beeswax, and carnauba wax combination.
- Claims 16 and 17 specifically cover capsule dosage forms.
- Xtampza ER is the principal commercial product associated with this technology.
- The patent is expected to provide protection into 2033, subject to the official term calculation and related patents.
- The most credible generic strategies are invalidity challenges based on obviousness and design-arounds avoiding the claimed salt-formation process.
- Biosimilar risk is irrelevant because the patent covers small-molecule formulations.
- A complete generic-entry analysis requires review of the full Orange Book patent family, not US 9,763,883 in isolation.
FAQs
Does US 9,763,883 cover all abuse-deterrent oxycodone formulations?
No. The formulation must use the claimed fatty-acid-salt and wax-based microparticle architecture and satisfy the process limitation in claim 1 or the narrower limitations of a dependent claim.
Does using oxycodone hydrochloride avoid US 9,763,883?
Not automatically. The answer depends on whether the product is made through the claimed free-base dissolution and fatty-acid salt-formation process and whether the resulting microparticles satisfy the composition limitations.
Is myristic acid required for infringement?
No. Myristic acid is required only by claim 8 and the oxycodone species claim 13. Claim 1 covers a broader group of fatty acids if the other limitations are met.
Can a hydrocodone product infringe US 9,763,883?
Yes, in principle. Claim 20 expressly identifies hydrocodone, but the product must also satisfy the fatty-acid-salt, wax-microparticle, molar-excess, and process requirements.
Does an Orange Book listing prove that a generic product infringes?
No. The listing identifies a patent asserted to cover an approved drug, formulation, or method. Infringement and validity remain separate legal questions.
References
- United States Patent and Trademark Office. (2017). U.S. Patent No. 9,763,883, Abuse-deterrent pharmaceutical compositions.
- U.S. Food and Drug Administration. (2016). Xtampza ER prescribing information. Collegium Pharmaceutical, Inc.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. ยง 355(j).
- Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009).
